Should we use E-SEMS or EVT for traumatic oesophageal perforations?

Although endoscopic self-expandable metal stents (E-SEMS) and endoscopic vacuum therapy (EVT) yielded similar clinical outcomes for the treatment of traumatic oesophageal perforations in the FORTAL trial, participants who underwent E-SEMS had a shorter hospital stay than those who underwent the EVT procedure. Moreover, the costs of E-SEMS were significantly lower than for EVT.

“Oesophageal perforation may lead to mediastinitis, empyema, sepsis, and eventually, organ failure,” outlined Dr Alessandrino Terceiro de Oliveira (Federal University of Ceará, Brazil) [1]. “Surgical interventions to tackle this issue are associated with a mortality rate of up to 20%.” The single-centre, randomised, double-blind, controlled FORTAL trial compared the efficacy of E-SEMS versus EVT in participants with a traumatic oesophageal perforation (n=30).

No significant differences were observed in clinical outcomes between the two arms. In the E-SEMS arm, 93.7% of the participants were discharged and 6.3% had deceased. The corresponding rates for the EVT arm were 71.4% (P=0.16) and 28.6% (P=0.16). Dr Terceiro de Oliveira added that the treatment duration was significantly longer in the E-SEMS arm than in the EVT arm (mean 45.8 days vs 24.4 days; P<0.05). In contrast, the length of hospital stay was significantly shorter among patients in the E-SEMS arm (number of days vs number of days; P=0.021). Finally, the mean cost of an E-SEMS procedure was substantially lower than the mean cost of an EVT procedure (€19,266 vs €38,453; P=0.013).

The current randomised-controlled trial provided insights into the differences between the 2 investigated surgical approaches in terms of treatment duration, length of hospital stay, and costs. Larger studies are needed to observe whether the procedures differ with regard to clinical outcomes.

1. 
   
   1. Terceiro de Oliveira A, et al. Endoscopic self-expandable metal stent (E-SEMS) versus endoscopy vacuum therapy (EVT) for traumatic esophageal perforations: the FORTAL randomized double-blind controlled comparative effectiveness trial. LB12, UEG Week 2023, 14–17 October, Copenhagen, Denmark.

Copyright ©2023 Medicom Medical Publishers



Posted on 7 December, 2023